Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
32 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Alchemia Ltd - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Alchemia Ltd - Product Pipeline Review - 2016', provides an overview of the Alchemia Ltd's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Alchemia Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Alchemia Ltd - The report provides overview of Alchemia Ltd including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Alchemia Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Alchemia Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Alchemia Ltd's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Alchemia Ltd - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Alchemia Ltd's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Alchemia Ltd Snapshot 5 Alchemia Ltd Overview 5 Key Facts 5 Alchemia Ltd - Research and Development Overview 6 Key Therapeutic Areas 6 Alchemia Ltd - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Alchemia Ltd - Pipeline Products Glance 11 Alchemia Ltd - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Alchemia Ltd - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 Alchemia Ltd - Drug Profiles 14 HA-5FU - Drug Profile 14 Product Description 14 Mechanism Of Action 14 R&D Progress 14 HA-Doxorubicin - Drug Profile 15 Product Description 15 Mechanism Of Action 15 R&D Progress 15 irinotecan hydrochloride - Drug Profile 16 Product Description 16 Mechanism Of Action 16 R&D Progress 16 Monoclonal Antibody 2 to Target CD44 for Oncology - Drug Profile 20 Product Description 20 Mechanism Of Action 20 R&D Progress 20 Small Molecules for Respiratory, Oncology, Cardiovascular, Metabolic Disorders, Infectious Disease and Neurology - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 Small Molecules to Inhibit Glycosyltransferase for Bacterial Infections - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 Small Molecules to Inhibit Glycosyltransferase for Gram-Positive Bacterial Infection - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 Alchemia Ltd - Pipeline Analysis 24 Alchemia Ltd - Pipeline Products by Target 24 Alchemia Ltd - Pipeline Products by Route of Administration 25 Alchemia Ltd - Pipeline Products by Molecule Type 26 Alchemia Ltd - Pipeline Products by Mechanism of Action 27 Alchemia Ltd - Dormant Projects 28 Alchemia Ltd - Discontinued Pipeline Products 29 Discontinued Pipeline Product Profiles 29 ACL-16907 29 VAST Based Drug For Obesity 29 Alchemia Ltd - Locations And Subsidiaries 30 Head Office 30 Other Locations & Subsidiaries 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 31 Disclaimer 32
List of Tables
Alchemia Ltd, Key Facts 5 Alchemia Ltd - Pipeline by Indication, 2016 8 Alchemia Ltd - Pipeline by Stage of Development, 2016 9 Alchemia Ltd - Monotherapy Products in Pipeline, 2016 10 Alchemia Ltd - Phase II, 2016 11 Alchemia Ltd - Preclinical, 2016 12 Alchemia Ltd - Discovery, 2016 13 Alchemia Ltd - Pipeline by Target, 2016 24 Alchemia Ltd - Pipeline by Route of Administration, 2016 25 Alchemia Ltd - Pipeline by Molecule Type, 2016 26 Alchemia Ltd - Pipeline Products by Mechanism of Action, 2016 27 Alchemia Ltd - Dormant Developmental Projects,2016 28 Alchemia Ltd - Discontinued Pipeline Products, 2016 29 Alchemia Ltd, Subsidiaries 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.